Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine is not influenced by AB0 blood group in subjects with transfusion-dependent thalassemia

Acta Biomed. 2022 May 11;93(2):e2022134. doi: 10.23750/abm.v93i2.12819.

Authors

Nicola Sgherza¹, Stefania Zucano², Angelantonio Vitucci², Antonio Palma³, Daniela Campanale², Angela Maria Vittoria Larocca², Domenico Visceglie², Amalia Acquafredda², Pellegrino Musto⁴

Affiliations

¹ a:1:{s:5:"en_US";s:147:"Hematology and Bone Marrow Transplantation Unit - AOUC Policlinico, Department of Emergency and Organ Transplantation, "Aldo Moro" University, Bari";}. nicolasgherza@libero.it.
² . nicolasgherza@libero.it.
³ . nioclasgherza@libero.it.
⁴ . pellegrino.musto@uniba.it.

Abstract

Not applicable.

MeSH terms

Antibodies, Viral
Antibody Formation
BNT162 Vaccine
Blood Group Antigens*
COVID-19 Vaccines
COVID-19* / prevention & control
Humans
SARS-CoV-2
Thalassemia* / genetics
Thalassemia* / therapy
Vaccines, Synthetic
mRNA Vaccines

Substances

Antibodies, Viral
Blood Group Antigens
COVID-19 Vaccines
Vaccines, Synthetic
mRNA Vaccines
BNT162 Vaccine